Editors:
- The volume will provide readers with a primer on tyrosine kinase signaling and its importance in cancer
- The reader will be first introduced to common denominators of small-molecule and antibody-derived inhibitors, and with the general phenomemon of resistance
- Then specific reviews will focus on resistance to the most commonly used classes of tyrosine kinase inhibitors, namely BCR-ABL1, FLT3, the HER family members, angiokinase family members, ALK and the Raf/MEK/MAPK pathway
- Includes supplementary material: sn.pub/extras
Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics (RTACT)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (7 chapters)
-
Front Matter
About this book
The volume will serve as a primer on tyrosine kinase signaling and its importance in cancer. The volume will first introduce the common denominators of small-molecule and antibody-derived inhibitors, as well as the general phenomenon of resistance. The volume will then detail resistance to the most commonly used classes of tyrosine kinase inhibitors, and will focus specific chapters on resistance to BCR-ABL1, FLT3, angiokinase family members, and ALK inhibitors.
Editors and Affiliations
-
Pisa University Hospital, Pisa, Italy
Daniele Focosi
About the editor
Dr.Daniele Focosi was born in Lucca (Italy) in 1980. He graduated in Medicine with full grades in 2005 at the University of Pisa, and completed specialization in hematology in 2009. He achieved a Ph.D. degree in Clinical and Fundamental Virology in 2014, and a master degree in Clinical Trials in Oncology-Hematology in 2014.
He has authored 106 peer-reviewed manuscripts indexed on PubMed, for a total h-index of 16 and an overall impact factor of over 1400 points. He has been a fellow of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Trieste, and of the Collegio Ghislieri in Pavia, Italy. He is currently employed full-time at the Pisa University Hospital, where he is also a member of the Faculty of the PhD School in Clinical and Translational Sciences at University of Pisa.
He has given 37 oral and 47 poster presentations at international medical congresses, and is member of the editorial board of 17 peer-reviewed journals. He has received awards from the European Federation of Immunogenetics, the European Society for Organ Transplantation, the Italian Society for Hematology, the Italian Interregional Transplant Association, the Italian Bone Marrow Donor Association, the Italian Society for Experimental Hematology, the Italian Society against Leukemia/Lymphoma/Myeloma.Bibliographic Information
Book Title: Resistance to Tyrosine Kinase Inhibitors
Editors: Daniele Focosi
Series Title: Resistance to Targeted Anti-Cancer Therapeutics
DOI: https://doi.org/10.1007/978-3-319-46091-8
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer International Publishing Switzerland 2016
Hardcover ISBN: 978-3-319-46090-1Published: 14 November 2016
Softcover ISBN: 978-3-319-83438-2Published: 30 April 2018
eBook ISBN: 978-3-319-46091-8Published: 07 November 2016
Series ISSN: 2196-5501
Series E-ISSN: 2196-551X
Edition Number: 1
Number of Pages: XIII, 188
Number of Illustrations: 2 b/w illustrations, 6 illustrations in colour
Topics: Cancer Research